Abstract:Emily Nizialek, 1 Emmanuel S Antonarakis 1, 2 1 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; 2 Department of Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA Correspondence: Emmanuel S Antonarakis Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD 21287, USA Tel +1 410-502-8341 Fax +1 410-614-7287 Email eantona1@jhmi.edu Poly (ADP-ribose) polymerase inhibitors (PARPi) are a unique class of antineoplastic agents that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either another agent or an underlying genetic alteration together lead to overwhelming DNA damage and ultimately cell death. PARPi first showed promise as a cancer therapy in patients with BRCA1/2 mutations and have become part of standard treatment for breast and ovarian cancer. In prostate cancer, two PARPi, rucaparib and olaparib, have been FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). While both agents are approved for tumors with BRCA1/2 alterations, for olaparib the indication is also expanded to patients with 12 other homologous recombination deficiency (HRD) gene alterations including ATM and PALB2 . PARPi differ in their pharmacokinetics and pharmacodynamics, and additional studies are being conducted with niraparib, veliparib, and talazoparib in prostate cancer. While PARPi are fairly well tolerated, common toxicities include hematologic (anemia/thrombocytopenia) and gastrointestinal effects (nausea/vomiting). Ongoing studies are being conducted combining PARPi with other agents in patients with and without HRD alterations. Early data are promising for the combination of PARPi with second-generation antiandrogens and with immunotherapy. As additional trials are developed and reported, the hope is that the patient population who may benefit from PARPi will continue to expand. Keywords: PARP inhibitor, prostate cancer, homologous recombination

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review

Prostate cancer and PARP inhibitors: progress and challenges

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence

New Therapeutic Opportunities

[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations]

Development of PARP inhibitors in advanced prostate cancer

A review of PARP inhibitors: from bench to bedside

PARP inhibitors alone or in combination for prostate cancer

PARP inhibitors in prostate cancers, is it time for combinations?

Leveraging PARP-1/2 to Target Distant Metastasis

PARP inhibitors in prostate cancer: clinical applications

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date

Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer

PARP Inhibitors for Breast Cancer Treatment

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency

Advances, Challenges, and the Landscape of PARPi Therapy—A Narrative Review

Effectiveness and Safety of Poly (Adp-Ribose) Polymerase Inhibitors in Cancer Therapy: A Systematic Review and Meta-Analysis

The role of PARP in DNA repair and its therapeutic exploitation

Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials